Generation of novel small-molecule drug targeting protein kinase epsilon for type 2 diabetes mellitus.
| Project/Area Number |
20810031
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied genomics
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
YONEZAWA Tomo Tokai University, 医学部, 奨励研究員 (60515964)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,302,000 (Direct Cost: ¥2,540,000、Indirect Cost: ¥762,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,742,000 (Direct Cost: ¥1,340,000、Indirect Cost: ¥402,000)
|
|---|
| Keywords | 2型糖尿病 / プロテインキナーゼCε(PKCε) / 低分子化合物 / トランスレーショナルリサーチ / マイクロサテライト解析 / ゲノム / 糖尿病 |
|---|
| Research Abstract |
We identified the susceptible gene as a protein kinase C epsilon(PKCε) for type 2 diabetes mellitus via genome-wide association study using microsatellites, prompting us to generate the small molecule drug targeting PKCε. Our in silico strategy using 60,000 chemical library identified several potential modulators of PKCε activity. We also confirmed the effect of modulators on molecular-and cell-based assay.
|
Report
(3 results)
Research Products
(4 results)
